MedTrace Logo

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07221032 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-14

No results posted yet for this study

Summary

This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.

Conditions

  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

BIOLOGICAL

FT836 CAR T cells (1 x 10^8 cells per dose)

FT836 CAR T cells will be administered by IV injection.

BIOLOGICAL

FT836 CAR T cells (3 x 108 cells per dose)

FT836 CAR T cells will be administered by IV injection.

BIOLOGICAL

FT836 CAR T cells (up to 9 x 108 cells per dose)

FT836 CAR T cells will be administered by IV injection.

DRUG

Daratumumab 16 mg/kg

Daratumumab will be administered intravenously.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Binod Dhakal, MD · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-03-31
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07221032 on ClinicalTrials.gov